During recent decades the doctrine of informed consent has become a standard part of medical care as an expression of patients' rights to self-determination. In situations when only one treatment alternative exists for a potential cure, the extent of a patient's self-determination is constrained. Our hypothesis is that for patients considering a life-saving procedure such as bone marrow transplant (BMT), informed consent has little meaning as a basis for their right to self-determination. A longitudinal study of BMT patients was undertaken with four self-administered questionnaires. Questions centered around expectations, knowledge, anxiety and factors contributing to their decision to undergo treatment. Although the informed consent process made patients more knowledgeable about the treatment, their decision to consent was largely based on positive outcome expectations and on trust in the physician. Informed consent relieved their anxieties and increased their hopes for survival. Our conclusion was that the greatest value of the informed consent process lay in meeting the patients' emotional rather than cognitive needs. When their survival is at stake and BMT represents their only option, the patient's vulnerability puts a moral responsibility on the physician to respect the principle of beneficence while not sacrificing the patient's right to self-determination. Keywords: informed consent; understanding; trust; beneficence; patient autonomy A patient undergoing a very complex and potentially lifesaving procedure such as a bone marrow transplant (BMT) is required to make difficult decisions based on extensive and complicated information. The difficulties of the decision-making process are exacerbated by the emotionally and physically demanding circumstances surrounding a potentially terminal illness. By virtue of having a particular life-threatening illness, patients are, so to speak, 'forced' to consider BMT if they are to have a chance to survive in the long term. In such situations, their voluntariness to consent is constrained.
cation for informed consent is applicable not only to BMT but also to other potentially life-saving interventions. Using this perspective, the concept of 'informed consent' may have a unique meaning to patients who need such interventions.
Several issues surface in considering informed consent, such as trust, the patient's autonomy, understanding and recall of information, and content of disclosure by the physician. The present study concerns itself with the relative significance of all these areas to BMT patients in their decision to give consent to treatment.
Definition of informed consent
A legally derived doctrine, informed consent is a hybrid concept, speaking both to the patient's right to self-determination and to the physician's obligation to disclose information about a procedure to the patient. From an ethical standpoint, the notion of informed consent is based on an egalitarian patient-physician relationship, where the patient is an autonomous person who has the right to make treatment decisions for him/herself. Most commonly, four basic criteria have to be met for informed consent: disclosure, understanding, voluntariness and competence. For the purposes of this study, we use the following definition: . . .'informed consent is given if a patient/subject with (1) substantial understanding and (2) in substantial absence of control by others (3) intentionally (4) authorizes (or refuses) a professional to do X.' 1 
Review of the literature
Relatively little data exist on informed consent in the context of BMT. [2] [3] [4] [5] [6] [7] Examination of patients' decision-making process over time through longitudinal research designs, in particular, is rare.
Research studies on informed consent for experimental cancer treatments in general, show that patients tend not to recall information on risks and complications. 8, 9 The studies of BMT patients in particular, conclude that patients do not give much weight to such information in their decisionmaking process. The survival motive, trust in the physician and fear of worsening of the disease are the most salient factors for participating in the treatment. The notion of constrained voluntariness regarding patients' consent due to the nature of their particular illness and treatment is relevant to BMT patients. The general concept has been discussed in the work by the President's Commission for the Study of Ethical Problems in Medicine and Biomedical & Behavioral Research 10 and by Patenaude et al. 2 The authors of the latter article emphasize a 'therapeutic rationale', more than the autonomy rationale as a basis for informed consent in BMT. In discussing the potentially detrimental influences of patient anxiety and the vast amount of complex and technical information relevant to BMT, Patenaude et al conclude that it is impossible for the physician not to select and edit the information that is conveyed to the patient. Thus, by stressing the primary, but not exclusive, duty of the physician to preserve human life and improve the patient's health (beneficence) more than the patient's right to information and self-determination (autonomy), they subscribe to a 'therapeutic rationale' for informed consent in the context of BMT. Lesko et al 7 shed further light on this perspective. Their findings indicate that the majority of adult BMT patients and parents of children undergoing BMT expressed difficulty in reaching an autonomous decision and depended largely on the physician's advice. Physicians, in the same study, perceived between one third and one half of the adult patients and parents as being passive in their decision-making.
Hypothesis
The above findings and deliberations led us to formulate the following hypothesis: in the context of a potentially life-saving procedure without any viable treatment alternatives for a potential cure, 'informed consent' has little significance to the patient in terms of his or her autonomous decision to proceed with treatment and that other factors influence the patient's decision decision-making process.
Objectives
In testing the above hypothesis, the objective of the study was to clarify and evaluate the basis of 'informed consent' for patients undergoing a bone marrow transplant. More specifically, the study examined (1) the patients' knowledge, concerns, level of anxiety and perceived level of understanding of the procedure; and (2) the factors that most strongly contribute to a patient's decision to proceed with the treatment. Based on the findings, we address the ethical implications for the informed consent process.
BMT at Albany Medical Center
Albany Medical Center (AMC) is a 625-bed, tertiary care academic health center, serving 17 counties in northern New York state and surrounding states. Its BMT program was initiated in 1994. When the current study began in the summer of 1995, a total of 25 transplants had been undertaken. The number of transplants performed in 1996 was 35 and in 1997 the number was 24. Fifteen procedures were performed during the first 6 months of 1998. Approximately 90% of all procedures have been autologous transplants.
Pre-treatment and consent process
At AMC the informed consent process takes place according to pre-established protocols in conjunction with the patients' pre-treatment phases. During the first clinic visit, the physician reviews with the patient and family the basic transplant process, its objectives, issues surrounding eligibility and the potential protocol. Other treatment options, if viable, are also reviewed. Time is set aside for the patient to ask questions and printed material on the procedure is given out. Before the next visit, the patient is given the opportunity to call the nurse and/or doctor with questions, speak with their own doctor, and with past BMT patients before they decide whether to proceed or not. The next phase includes a history and physical in the clinic and standard chemotherapy, depending on disease and stage. Tests are performed to determine if the patient is an appropriate candidate. If the patient is determined to be eligible, the formal informed consent process begins with more specific information provided and a time line set for the treatment procedures. Patients receive a copy of the consent form to read and to discuss with their family and physician. They are given the opportunity to meet with individuals who have undergone the procedure. Patients are also given a tour of the BMT unit and the pheresis area. During the last clinic visit before hospital admission, the treatment team discusses the consent with the patient and any questions they may have before the form is signed. The process described is in addition to the conveying of information to the patient by their referring physician prior to the first clinic visit.
Methods
Design: This study employed a longitudinal design following patients at four points in time: at their first and second BMT clinic visits, at the time of hospital admission and finally at 3 months post treatment. The time period between the first visit and admission to the hospital ranged between 6 weeks and 5 months.
For the initial contact at the time of the patients' first visit for evaluation, they were approached by the clinic/project nurse in the waiting room, before their encounter with the physician, and were asked to participate in the study (time 1). After giving consent, patients were asked to complete a self-administered questionnaire while waiting to see the physician. Patients were given the second questionnaire at their next clinic visit and again asked to complete it while waiting for their appointment with the physician (time 2). If a patient had no time or did not feel well enough to complete the questionnaire at their second visit they were contacted at home by telephone by a research assistant who requested that they complete the questionnaire at home and return it via the mail. The third questionnaire was given to the patient at the time of their admission to the hospital for their transplant procedure (time 3), and the fourth was sent to the patient at home approximately 3 months after their discharge (time 4). Data were collected over a period of 19 months ending on 31 January 1997.
The study was approved by the institutional review board of Albany Medical College.
Sample selection: All new adult patients referred to the clinic were considered eligible for the study. Other than age (18 and over), no exclusion criteria were used. Recruitment for the study took place from June 1995 to September 1996.
Attrition: A total of 56 patients was asked to participate in the study. Five individuals declined to participate due to factors related to their illness. The remaining 51 completed the first questionnaire. For the first follow-up (time 2) the response rate dropped to 17 patients. Table 1 shows the status of those subjects who did not participate in the follow-up phase. As the information indicates, the steep decrease in sample size was primarily due to the subjects' illness status rather than refusal to participate. None of the 34 patients who were lost to the study underwent a BMT at Albany Medical Center.
Fourteen participants completed the time 3 questionnaire at the time of their hospital admission. Attrition between time 2 and time 3 was due to ill health (one patient) and death (two patients). Thirteen patients responded to the last questionnaire 3 months post discharge. The 14th subject could not be located. While the follow-up sample was small, the total population who did have treatment at AMC (with the exception of one subject) completed the study. Table 2 describes the characteristics of the sample at the time of the patients' first visit and at first follow-up. Almost two-thirds of the sample were females. The mean age was 42.1 years, with a range of 18-63. Educational level reflected a highly educated group. Consistent with the subjects' educational background, slightly over one third held professional occupations as compared to less than one fifth who had semi-skilled or unskilled jobs. With regard to living arrangements, a very small minority of the patients lived alone. Most of them lived with family members of whom 80.0% (36) were spouses.
Sample characteristics:
As Table 2 indicates, the follow-up sample (n = 17) had similar age and gender characteristics to the original group, but comprised fewer people living alone and a larger proportion with higher education.
Gender distribution was reflected in types of diagnoses presented in the sample. As shown in Table 2 , the majority had breast cancer, followed by, non-Hodgkin's lymphoma, Table 1 Reasons for not participating in follow-up Hodgkin's disease and brain cancer. Other diagnoses included ovarian cancer, leukemia, and multiple myeloma. In comparison to the initial sample, the diagnoses represented in the follow-up sample included a higher proportion of individuals with breast cancer.
All but two of the participants (88.3%) underwent autologous transplants, thus being a representative group of the total transplant population at AMC.
The questionnaires: The questionnaires were developed by the research team and pretested on BMT patients at AMC. Modifications to the questions were made based on input from the pretest. Each of the four questionnaires was semistructured in nature and varied in length from 15 questions for times 1 and 2 to 10 questions for times 3 and 4. While questions about how the patient had heard about BMT prior to their first clinic visit were unique to the first questionnaire, the basic content was the same for most of the questions across each administration. A 10-point scale measuring anxiety was consistent over time, and another scale assessing subjects' outcome expectations was used in the first three questionnaires. Questions 3 months post discharge addressed the patient's assessment of the treatment and the information they received, as well as their most pressing concerns. Responses to open-ended questions were content analyzed and coded along commonly occurring themes.
Reliability and validity of the instruments will be tested further through replication of the study with BMT patients and patients with other life-threatening illnesses undergoing different procedures.
Data analysis
Data management and analysis were performed with the use of SPSS/PC. Frequency distributions provide a profile of the whole sample at time 1. In order to control for any bias represented by the subset of the 17 subjects who underwent treatment and completed the study, data for this group were analyzed and are described separately.
Limitations
One limitation of the study is the lack of a comparison group. In an effort to capture the role of informed consent in electing not to proceed with treatment or choosing to go elsewhere, a separate questionnaire was sent to the 14 patients in this category. Only two of these questionnaires were completed and returned. It is safe to assume that there was little motivation or opportunity among the remaining 12 individuals at that time to respond to a questionnaire. Further limitations include the lack of data available on the type and extent of information conveyed to patients by their referring physician and the constrained generalizability due to a small sample size.
The 17 subjects who remained in the study (follow-up sample) constitute a self-selected group in being eligible for the transplant procedure.
Results

Knowledge about BMT
Three quarters of the respondents had heard about BMT before being referred to the clinic at AMC for evaluation. The original sources of information included the referring physician (oncologist, 80.4%/41 or hematologist, 21.6%/11), mass media (33.3%/17), family or friends (19.6%/10) and other patients (11.8%/6).
Ten percent (five) of the participants had originally learned about the procedure through their own research before referral. The proportion rose to 45.1%/23 having done their own research between time of referral and first clinic visit. The most common sources used for research were local or national organizations, a library, other patients, the internet, and literature obtained from friends, colleagues and others. The large majority (86.3%/44) reported that they were planning to continue or start their own research after their clinic visit. Separating out the data for the sub-sample (n = 17) who had treatment revealed that a relatively high proportion -76.5%/13 -of this group had done their own research prior to their first clinic visit. This compares to 29.4%/10 of the 34 subjects who did not complete the study.
The extent to which respondents felt they could describe the BMT procedure at the time of their first clinic visit (before being seen by the BMT team) was modest, with only 7.8%/4 being able to describe the process in detail at that time. Table 3 shows that over time, however, the subjects' knowledge level increased dramatically so that at the time of their hospital admission as many as 85.7%/12 felt Table 3 Changes over time in ability to describe BMT they were able to describe the treatment process very well. Those in the follow-up sub-sample generally reported a better ability to describe the treatment at the time of their first clinic visit than the subjects who did not complete the study.
At 1st visit At 1st visit At 2nd visit At admission n
= 51 n = 17 n = 17 n = 14 % (n) % (n) % (n) % (n)
Patients' perceived need for information
The significant need for information about the BMT process felt by patients during their first clinic visit is reflected in the large proportion (82.4%/42) stating that they had unanswered questions about the procedure. When asked to specify their questions, 40.5%/17 did not mention any. However, three quarters of the remainder articulated more than one of nine different questions mentioned specifically, such as rate of success, the nature of the treatment process, amount of time to be spent in the hospital, the recovery course and side-effects and complications. The proportion who still had unanswered questions at the time of their second visit dropped to 35.3%/6. The follow-up sub-sample again differed from the rest of the subjects in that the proportion with unanswered questions at time 1 was higher -94.1% vs 76.5%. When asked to describe the treatment based on information they had received up to that point in time, most participants mentioned the high dose of chemotherapy, the extraction of immune cells and the storage of such cells. It is noteworthy that risks and complications were not mentioned even though the large majority reported having been informed about these factors.
Anxiety, concerns and outcome expectations at time 1
Anxiety: An assessment of the patients' anxiety on a scale from 1 (not high) to 10 (very high) at the time of their first clinic visit, showed an overall moderate level at 6.7. The average level of anxiety was highest regarding the BMT procedure (7.3), followed by anxiety about the illness (6.7) and about the clinic visit (6.1). Examining anxiety levels in the follow-up vs no follow-up sub-samples showed that the former group consistently expressed more anxiety across all three variables -the BMT, their illness and the visit.
Concerns:
As would be expected, many of the initial concerns expressed among the respondents had to do with success rate, the recovery process and complications. However, issues of a more emotional and/or existential nature, such as survival, the possibility of death and having to be away from family, were also mentioned as prominent concerns at the time of their first visit. While more than one third (37.3%/19) of the participants expressed more than one concern at the time of their first visit, 17.6%/9 reported no concerns. The latter finding could be explained by patients' not having had sufficient information at that time, or not having had an opportunity to digest the information conveyed.
Separating out the 17 participants who proceeded with treatment showed that, at the time of their first visit, they were more likely to express concerns about being away from family members and less likely to report concerns about side-effects and complications in comparison with the other patients. The two subsets of patients were comparable with regard to types and prevalence of other self-reported concerns.
Outcome expectations: While most participants expressed their concerns and rather significant levels of anxiety about BMT, their illness and their clinic visit at time 1, their average level of expectation for a positive treatment outcome was moderately high at 6.9 on the 10-point scale. Despite higher initial anxiety among the 17 subjects who proceeded with treatment, this group demonstrated more positive outcome expectations at the time of their first visit to the clinic, with an average score of 8.0. This compares to 6.4 for the subjects who did not have treatment.
Changes in anxiety, concerns and outcome expectations over time
Anxiety: In order to make valid comparisons of changes over time, data from time 1 are based on the follow-up subsample only. Self-reported levels of anxiety at each point in time revealed that patients were consistently quite anxious about their illness and about the procedure during the pre-treatment period but experienced less anxiety at the time of hospital admission. (Table 4 ). The latter may reflect the fact that a period of anticipation and uncertainty had passed for these individuals, and that they had now taken a concrete step in the treatment process. At the time of their hospitalization, the majority (78.6%/11) of the subjects stated that clinic staff had been helpful in alleviating their anxieties and concerns. They also reported that their interactions had made them feel positive and hopeful. As shown in Table 4 , anxiety about the clinic visits was relatively low and decreased more notably between the two visits. This is likely due to the fact that at their second clinic visit patients were familiar with the staff, and had been informed that they were eligible candidates for the procedure. The average level of general anxiety three months after treatment was 4.1.
Concerns:
The nature of the concerns expressed by the patients at their second visit remained largely the same as during their first visit. At the time of hospitalization, however, patients tended to report concerns of a more medical nature as compared to the pre-treatment visits. At 3 months after discharge, the most prevalent concerns revolved around the inability to participate in daily activities and to perform on the job.
Outcome expectations: While levels of anxiety remained relatively high during the pre-hospital admission phase, expectations for a good treatment outcome rose from an already high average level of 8.0 at time 1 to 9.4 at the second visit and 8.6 at time of hospital admission.
Factors influencing decision making
At their second visit to the clinic, the 17 study participants were asked to rank the level of importance that they attached to the following four factors for their decision to proceed with BMT: (1) a full understanding of the treatment, (2) trust in the physician, (3) trust in the treatment team and (4) best chance for a good outcome. Four individuals who ranked all factors equally as 'most important' have been excluded from the analysis. As shown in Table 5 , 'the best chance for a good outcome' outweighed the other factors as most important in impacting the patients' decision to undergo treatment. Combining the 'very important' and 'most important' rankings showed that the factors involving trust played a significant role in the patients' decision-making. Having a full understanding of the BMT procedure, on the other hand, was rated as the least important of the four factors. Interestingly enough, almost half of the group (47.1%/8) stated that they had made their decision to go ahead with the treatment prior to their first visit to the BMT clinic. This is not consistent with the BMT program protocols as Table 5 Importance of factors in deciding to proceed with BMT at 2nd visit (n = 13) Four subjects who ranked all factors equally as 'most important' are excluded from the analysis.
described earlier. Nevertheless, it underscores the fact that the treatment constitutes, if not the only, at least the best treatment alternative available and that being fully informed about its nature and process was not the most significant factor for the individual. When asked how important the information from the BMT physician was for their decision, three quarters (76.5%/13) stated it was 'very important.' Elaborating on this point, these subjects felt that the communication process helped to alleviate their fears and to maintain their hopes and expectations for a good outcome.
The latter was confirmed further in the participants' response to an open-ended question about the main reasons for selecting BMT over other options, where 64.7%/11 mentioned that this was their 'only option' and 70.6%/12 stated that BMT was 'a possible cure.'
BMT information and level of understanding 3 months after treatment
Three months after hospital discharge all 13 patients responded affirmatively when asked if the information presented to them throughout the process had been understandable. When asked if the information they had received accurately reflected the BMT procedures, all but one participant gave a positive response. Upon further reflection, however, four patients (30.8%) commented that it was 'not possible to fully explain' all the aspects of the treatment, whereas another four patients stated that the treatment had not been as difficult as had been described by staff. These responses appear to indicate that the information obtained through the informed consent process had been adequately understood by the patients.
Discussion
The findings of this study support the hypothesis that patients gave relatively little weight to understanding the information given to them during the informed consent process. A more significant factor was their trust in the physician. Most important of all, however, was the fact that BMT was their best and only viable alternative for prolonged survival, which is consistent with findings from other research cited earlier.
The inference one can draw from these results is that informed consent in BMT meets patients' emotional needs more so than their cognitive needs. The notion of being informed and gaining an understanding for purposes of decision-making appeared to have little salience for the patients in this study. While becoming informed was not considered unimportant by the patients, and while, in their own view, they became well-informed during the pre-treatment phase, the consent process served primarily to establish trust with the physician and staff. Trust was built during the process of information-sharing and on the opportunity for the subjects to express and have addressed their fears, concerns and questions. The trust, they felt, in turn helped them maintain hope for a positive outcome. This interpretation is consistent with Patenaude et al's 2 proposition of a 'therapeutic rationale' for informed consent rather than a rationale based on autonomy.
The patient
The findings of this study raise issues that have implications for informed consent, not only in BMT, but in other stressful, complex, highly technological and risky procedures where the patient's survival is at stake. The patient is vulnerable in at least two respects. First, their life-threatening illness and limitations on effective medical care options put constraints on their voluntariness in the strict sense of the word. The President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research states that '. . .patients who have the capacity to make decisions about their care must be permitted to do so voluntarily. . .' (p. 2) 10 In treatment situations like BMT, however, where no other viable options exist for a cure, or when the preferred choice is the least difficult one among other difficult alternatives, the illness condition itself is sometimes referred to as 'coercive', in that the patient's voluntary capability to give consent is limited. This perspective may be reflected in the study subjects' perceptions of the significance of 'a good outcome' as the prominent factor in their decision-making. It was only at the first clinic visit that some patients mentioned considering other treatment options. It is important to note that at that point in time, eight patients did chose not to proceed with the BMT treatment. Unfortunately, we do not know why they made this decision and what other treatment options they pursued. The significance is that they apparently exercised their voluntary choice at that juncture.
Second, patients are vulnerable because they do not place a high value on having a sound cognitive understanding of the information conveyed to them, which is normally a criterion for giving informed consent. This is true in spite of the subjects' claims that they felt they understood the procedures described to them and the fact that they were highly educated. When illnesss and treatment contexts themselves constrict voluntary capability in patients, understanding with regard to informed consent may become less relevant.
The patient-physician relationship
Because of the inherent constraints related to patients' voluntariness to give consent in the context of BMT, it follows that the patient-physician relationship reflects a fundamental power imbalance. The physician's recommendations for any therapy are likely to receive acceptance from patients in this situation regardless of the patient's interest in and understanding of relevant information for decisionmaking. Therefore, the relationship is based largely on trust, hope and mutual respect more so than on truly informed and voluntary consent. As such, the relationship can be characterized as fragile. In such circumstances, the principle of beneficence takes on heightened importance as a basis for the physician's moral posture toward the patient. Compassionate, clear and thorough dialogue between the patient and the physician is of paramount significance. The physician is placed in a delicate position of ensuring that a fair appraisal of the risks and benefits of treatment is transmitted, and that the patient is allowed the greatest degree of comfort in giving consent to treatment. We believe the 'therapeutic rationale' for informed consent in the BMT setting should serve as a vehicle for managing the vulnerability of the patient in the context of meaningful beneficience-based, patient-physician interaction, patient education and trust-building. Concommitantly, in helping the patient reach the greatest level of accomodation to her sitution, the physician shows respect for patient autonomy, thus maximizing the patient's empowerment. This perspective leads us to propose that in BMT and procedures of a similar nature, a synthesis is necessary between the ethical principles of beneficence and patient autonomy as the basis for informed consent.
Conclusion
In conclusion, the study findings suggest that consent to a complex life-saving procedure, such as BMT, is given by patients based largely on their perception that the treatment offers them their only real hope for success. It requires them to place their trust in the physician and the health care team. Although the patients were informed and largely felt they understood the information, this consideration was not a significant basis for their decision. Such situations of reduced patient voluntariness and increased vulnerability put a great moral responsibility on the physician and the other team members to ensure that they, at all times, are guided by the principle of beneficence, always attempting to promote the best interests of the patient, without regard to self interest or other contextual factors, and maintaining their respect for the patient's autonomy so as to empower the patient as much as possible.
Further research is required to determine the generalizability of the findings to other BMT programs and to other life-saving procedures. Additionally, there is a need to investigate the role of informed consent for patients who decide not to proceed with treatment.
